Key Takeaways
Sarepta Therapeutics ( SRPT ) reported that a patient with Duchenne muscular dystrophy taking its Elevidys treatment died of acute liver failure (ALF). Shares plunged 23% on the news.
The pharmaceutical firm noted that "acute liver injury is a known possible side effect of Elevidys" and other similar gene therapies, although this was the first time a death had been reported of anyone taking the drug.
Sarepta explained that the patient had recently suffered from a cytomegalovirus (CMV) infection, "which was identified by the treating physician as a possible contributing factor."
The company said it continues to gather and analyze information from the incident, and it has been reported to health authorities. Sarepta also plans to update its prescribing information "to appropriately represent this event."
Investopedia has reached out to the company to see if it may be considering taking any other actions in light of this incident.
Including today's sharp declines, shares of Sarepta Therapeutics have lost more than 35% of their value in the last year.
Read the original article on Investopedia